Erythrocyte based delivery system of primaquine:<i>in vitro</i>characterization

Talwar, Naresh; Jain, Nitin

doi:10.3109/02652049209021250

Cited by 21 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cell recovery of loading process was 87-93%, this is practically better than the recovery results of other studies such as primaquine and enalaprilat 33, 34. This result is may be an evident to the quite effect of loading process on erythrocytes and/or protective effect of pravastatin as investigated in previous study stated that the pravastatin protect erythrocytes against oxidative damage induced by drugs 35.…”

Section: Resultsmentioning

confidence: 58%

Characterization of Human Erythrocytes as Potential Carrier for Pravastatin: An In Vitro Study

Harisa¹,

Ibrahim²,

Alanazi³

2011

Int. J. Med. Sci.

View full text Add to dashboard Cite

Drug delivery systems including chemical, physical and biological agents that enhance the bioavailability, improve pharmacokinetics and reduce toxicities of the drugs. Carrier erythrocytes are one of the most promising biological drug delivery systems investigated in recent decades. The bioavailability of statin drugs is low due the effects of P-glycoprotein in the gastro-intestinal tract as well as the first-pass metabolism. Therefore in this work we study the effect of time, temperature as well as concentration on the loading of pravastatin in human erythrocytes to be using them as systemic sustained release delivery system for this drug. After the loading process is performed the carriers' erythrocytes were physically and cellulary characterized. Also, the in vitro release of pravastatin from carrier erythrocytes was studied over time interval. Our results revealed that, human erythrocytes have been successfully loaded with pravastatin using endocytosis method either at 25oC or at 37oC. The loaded amount at 10 mg/ml is 0.32mg/0.1 ml and 0.69 mg/0.1 ml. Entrapment efficiency is 34% and 94% at 25oC and 37oC respectively at drug concentration 4 mg/ml. Moreover the percent of cells recovery is 87-93%. Hematological parameters and osmotic fragility behavior of pravastatin loaded erythrocytes were similar that of native erythrocytes. Scanning electron microscopy demonstrated that the pravastatin loaded cells has no change in the morphology. Pravastatin releasing from carrier cell was 83% after 23 hours in phosphate buffer saline and decreased to 72% by treatment of carrier cells with glutaraldehyde. The releasing pattern of the drug from loaded erythrocytes obeyed first order kinetics. It concluded that pravastatin is successfully entrapped into erythrocytes with acceptable loading parameters and moderate morphological changes, this suggesting that erythrocytes can be used as prolonged release for pravastatin.

show abstract

Section: Resultsmentioning

confidence: 58%

Characterization of Human Erythrocytes as Potential Carrier for Pravastatin: An In Vitro Study

Harisa¹,

Ibrahim²,

Alanazi³

2011

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…In general, kinetics of the drug release from erythrocyte carriers depends on the size and polarity of the encapsulated agents . Three different patterns of drug release are possible: (i) the drug release occurs by rapid diffusion through the membrane for lipophilic drugs such as primaquin or methotrexate; (ii) the drug release occurs by cell lysis, i.e., hemoglobin release for polar drugs such as enalaprilat, gentamicin, and tramadol; and (iii) the release profile is intermediate between the first two patterns, as observed for erythropoietin and isoniazid . Although erythrocyte ghosts represent product of controlled hemolysis of erythrocytes (i.e., the majority of hemoglobin content is removed), some residual hemoglobin is always present in resulting bovine and porcine erythrocyte ghosts .…”

Section: Resultsmentioning

confidence: 99%

Biomembranes from slaughterhouse blood erythrocytes as prolonged release systems for dexamethasone sodium phosphate

Drvenica

Bukara

Ilić

et al. 2016

Biotechnology Progress

View full text Add to dashboard Cite

The present study investigated preparation of bovine and porcine erythrocyte membranes from slaughterhouse blood as bio-derived materials for delivery of dexamethasone-sodium phosphate (DexP). The obtained biomembranes, i.e., ghosts were characterized in vitro in terms of morphological properties, loading parameters, and release behavior. For the last two, an UHPLC/-HESI-MS/MS based analytical procedure for absolute drug identification and quantification was developed. The results revealed that loading of DexP into both type of ghosts was directly proportional to the increase of drug concentration in the incubation medium, while incubation at 37°C had statistically significant effect on loaded amount of DexP (P < 0.05). The encapsulation efficiency was about fivefold higher in porcine compared to bovine ghosts. Insight into ghosts' surface morphology by field emission-scanning electron microscopy and atomic force microscopy confirmed that besides inevitable effects of osmosis, DexP inclusion itself had no observable additional effect on the morphology of the ghosts carriers. DexP release profiles were dependent on erythrocyte ghost type and amount of residual hemoglobin. However, sustained DexP release was achieved and shown over 3 days from porcine ghosts and 5 days from bovine erythrocyte ghosts. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1046-1055, 2016.

show abstract

“…Delivery of primaquine was stabilized by loading them in RBC membranes which were treated with glutaraldehyde for liver targeting. The drug-loaded erythrocytes have a size of 5.55 µm which were smaller in size than normal RBCs (6.35 µm) ( Talwar and Jain 1992 ). To protect macrophage in murine AIDs, nucleoside analogues were loaded in glutathione-loaded erythrocytes which could deliver the payload drugs selectively to macrophages, thereby reducing the viral load ( Fraternale et al, 2002 ).…”

Section: Applications Of Red Blood Cell Membrane-derived Systemsmentioning

confidence: 99%

Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation

et al. 2022

View full text Add to dashboard Cite

Red Blood Cells (RBCs)-derived particles are an emerging group of novel drug delivery systems. The natural attributes of RBCs make them potential candidates for use as a drug carrier or nanoparticle camouflaging material as they are innately biocompatible. RBCs have been studied for multiple decades in drug delivery applications but their evolution in the clinical arena are considerably slower. They have been garnering attention for the unique capability of conserving their membrane proteins post fabrication that help them to stay non-immunogenic in the biological environment prolonging their circulation time and improving therapeutic efficiency. In this review, we discuss about the synthesis, significance, and various biomedical applications of the above-mentioned classes of engineered RBCs. This article is focused on the current state of clinical translation and the analysis of the hindrances associated with the transition from lab to clinic applications.

show abstract

Erythrocyte based delivery system of primaquine:in vitrocharacterization

Cited by 21 publications

References 10 publications

Characterization of Human Erythrocytes as Potential Carrier for Pravastatin: An In Vitro Study

Characterization of Human Erythrocytes as Potential Carrier for Pravastatin: An In Vitro Study

Biomembranes from slaughterhouse blood erythrocytes as prolonged release systems for dexamethasone sodium phosphate

Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation

Contact Info

Product

Resources

About